STICHTING CENTRE FOR HUMAN DRUG RESEARCH

Their core work

CHDR is a Leiden-based independent clinical research foundation specializing in early-phase human drug trials and pharmacological modeling. They conduct controlled human infection models, immune profiling studies, and quantitative systems pharmacology to bridge the gap between preclinical drug development and clinical application. Their core value lies in running sophisticated human challenge studies and translating computational drug models into real-world clinical insights, particularly for vaccines and pain therapeutics.

What they specialise in

How they've shifted over time

CHDR's early H2020 involvement (2019-2020) centered on computational pharmacology and personalized medicine — modeling drug combinations in silico for chronic pain treatment. By 2020-2021, their focus shifted decisively toward vaccine development, controlled human infection models, and AI-assisted manufacturing. This evolution reflects a broadening from drug-level modeling to population-level immunology and vaccine acceleration, likely catalyzed by the pandemic-era urgency around vaccine innovation.

CHDR is moving toward AI-integrated human challenge models for vaccine development — expect them to seek partners with AI/ML capabilities and mucosal immunology expertise.

How they like to work

CHDR operates exclusively as a participant or third-party expert — they have never coordinated an H2020 project, which is typical for specialized clinical research organizations that contribute deep domain expertise rather than project management. With 65 unique partners across 14 countries, they work in large international consortia (both INCENTIVE and Inno4Vac are major multi-partner projects). This pattern indicates a reliable specialist contributor that large consortia seek out for their human trial capabilities.

CHDR has built a broad European network of 65 unique partners spanning 14 countries, driven primarily by their participation in large vaccine and pharma consortia. Their base in Leiden places them in the heart of the Dutch life sciences corridor, well-connected to both academic and industry partners.

What sets them apart

CHDR occupies a rare niche as an independent, SME-scale clinical pharmacology center that can run controlled human infection models — a capability few organizations in Europe possess. Unlike university hospitals or large CROs, they combine the agility of a small specialized institute with deep expertise in early-phase human trials. For consortium builders, they offer a credible, experienced partner for any project requiring human challenge studies, immune monitoring, or pharmacological modeling without the overhead of a large academic institution.

Highlights from their portfolio

• Inno4Vac
  Largest single EC contribution (EUR 1.83M) — combines AI, controlled human infection models, and in vitro approaches to accelerate vaccine manufacturing, reflecting CHDR's strategic direction.
• QSPainRelief
  Demonstrates CHDR's computational pharmacology depth — uses quantitative systems pharmacology to find personalized drug combinations for chronic pain, bridging modeling and clinical validation.
• INCENTIVE
  Indo-European consortium for next-gen influenza vaccines — CHDR participates as third party, indicating they were brought in specifically for their human challenge trial expertise.